Dunn: prolapse, bleeding, menopause Flashcards

1
Q

prolapse types

A

bladder/ cystocele
bacpassage/ rectocele
womb/ uterine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

baden-walker halfway system

A
ervic at ischial spines- 0
halfway to hymen- 1
to the hymen - 2
halfway past hymen- 3
maximum descent- 4
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

prolapse Treatment Options

A
Nothing
Conservative Measures including Kegels, Weight Loss
Estrogen Cream
Pessary
Bladder Sling
Colposacropexy
Colpocleisis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Stress Incontinence

A

occurs with sneeze, cough, laugh, jog, or do other things that put pressure on your bladder. It is the most common type of bladder control problem in women.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Overactive Bladder

A

OAB defined based on symptoms

Urgency, with or without urge incontinence, usually with frequency and nocturia
In the absence of pathologic or metabolic conditions that might explain these symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Urge Incontinence

A

happens when you have a strong need to urinate but can’t reach the toilet in time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mixed Incontinence

A

This is a combination of

 Stress incontinence and urge incontinence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DIAPPERS

A

Delirium - addresses by toileting
Infection – urinary exacerbates incontinence and causes frequency and urgency
Atrophic urethritis and vaginitis – contribute to irritative symptoms
Pharmaceuticals – anticholinergics = detrusor underactivity-may cause retention; cholinergics = detrusor overactivity – may cause frequency;α-agonist=outlet overactivity - may cause retention;α-blockers = outlet underactivity – may cause stress incontinence
Psychological disorders – toileting
Excessive urine production – or physiologic or pharmacologic nocturia
Restricted mobility – toileting
Stool impaction - retention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Urodynamic Studies

A

Cystometry
- A study of bladder filling: the bladder is filled with fluid and pressures are measured

Uroflowmetry
- Measures of flow rate

Pressure - Flow
- Simultaneous measurement of bladder pressure during contraction with flow to assess degree of obstruction

Electromyographic Studies
- Stimulus evoked responses measure contractions and reflexes: most useful in conjunction with cystometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

dx of overactive bladder

A

most cases of overactive bladder can be dxed based on:

  • pt history, symptom assessment
  • physical exam
  • urinalysis

initiation of noninvasive treatment does not require an extensive further workup

(rule out DIAPPERS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

OAB–> disabling conditions

A

increased risk of hospitalization, admission to nursing homes, depression

UTIs and skin irritation

increased risk of falls and fractures (morbidity and mortality)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

barriers to tx of OAB

A

Pt misconceptions and fears (normal aging, not severe or frequent enough tot treat, too embarrassing to discuss, tx will not help)

physician concerns (no validated screening tools, nearly 2/3 are symptomatic for 2 years before seeking tx, 30% of pts who seek tx receive no assessment, nearly 80% not examined)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

nocturia

A

waking 1 or more times to void at night

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

PALM-COEIN classification for uterine bleeding in nongravid reproductive-age women

A

Polyp
Adenomyosis
Leiomyoma
Malignancy and hyperplasia

Coagulopathy
Ovulatory dysfunction
Endometrial
Iatrogenic
Not yet classified
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

algorithm for uterine bleeding

A
  1. rule out non-uterine source
  2. rule out pregnancy
  3. See how much bleeding it is and whether regular or not
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Endometrial Polyp

A

Hyperplastic overgrowths of endometrial glands and stroma that project from the surface of the endometrium
Common cause of perimenopausal and early postmenopausal uterine bleeding
Generally benign, but malignancy highest in postmenopausal women
Growth of polyps can be stimulated by estrogen therapy or tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Uterine Leiomyoma

A

Most common type of benign tumor in females
- Leiomyosarcoma is malignant variant

Symptoms

  • Asymptomatic
  • — Abnormal/painful menses
  • — Abdominal pain

Subtypes based on location

  • Pedunculated
  • Subserosal
  • Submucosal
  • Intramural
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Fibroids

A

Most common benign neoplasia of female genitals
Smooth muscle and connective tissue growth
E/P sensitive (will stop growing during pregnancy and menopause
Rarely (1.5%) become leiomyosarcoma
Complications: torsions and infertility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Adenomyosis

A

Triad=noncyclical pain, menorrhagia, enlarged uterus w/o adnexal tenderness
Endometrial tissue growth within myometrium
Tx: NSAIDs, OCPs, Progestins, ablation, hysterectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Fibroids (Uterine Leiomyomas) - risk factors, etc.

A

covering
Tend to increase over time as they are stimulated by estrogen
Most common noncancerous tumors of women of childbearing age
1/5 women greater than 30yo will have fibroids
Leading cause of hyterectomy in the US
Present usually with abnormal uterine bleeding or pelvic pain/pressure
Risk Factors
- Race: 2-3x higher in African Americans than Caucasians and tend to present earlier
- Menstrual history: early menarche (,10yo)
- Obesity
- Diet, alcohol: red meats, beer
- HTN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Uterine Fibroids (Leiomyomas) classification and treatment

A

Classified by position in the uterine wall

  • Intramural
  • Within uterine cavity: submucosal, pedunculated submucosal, pedunculated vaginal
  • Growing outward from the uterus-can be
  • – Cervical
  • – Subserous
  • – Intraligamentous
  • – Pedunculated subserous (abdominal)

Treatment Expectant management in those who are asymptomatic or decline medical or surgical treatment

  • Symptoms treatment to regulate bleeding (i.e. OCPs)
  • GnRH agonist but may return to pretreatment state once therapy is discontinued
  • Surgery: Myomectomy, endometrial ablation, Uterine artery embolization, hysterectomy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Uterine Leiomyoma-myxoid degeneration

A

Larger leiomyomas outgrow blood supply and undergo degeneration

Types of degeneration

  • Hyaline
  • Cystic
  • Red carneous
  • Myxoid
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Postmenopausal Bleeding

A

General Considerations

  • Uterine bleeding in menopausal women
  • Bleeding may be a single episode of spotting or profuse bleeding for days or months
  • Usually painless
  • – Pain present if cervix is stenotic, if bleeding is severe and rapid, or if infection, torsion, or extrusion of tumor is present

Incidence:
4-11% of postmenopausal women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Etiology of postmenopausal bleeding

A
Atrophic endometrium-59%
Endometrial polyps-12%
Endometrial cancer-10%
Endometrial hyperplasia-9.8%
Hormonal effects-7%
Cervical Cancer-<1%
Many who take estrogen therapy develop vaginal bleeding
Frequency depends upon the regimen used
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Atrophic Endometrium
Hypoestrogen causes atrophy of the endometrium and vagina results in microerosions which is prone to light bleeding or spotting Classic vaginal findings: pale, dry vaginal epithelium that is smooth and shiny with loss of most rugation
26
Endometrial Hyperplasia
Proliferation of endometrial glands resulting in greater gland-to-stroma ratio than observed in normal endometrium Postmenopausal women should be estrogen deficient, so endometrial hyperplasia is abnormal and requires an explanation Endogenous estrogen production from ovarian or adrenal tumors or exogenous estrogen therapy are possible causes Obese women have high levels of endogenous estrogen due to the conversion of androgens to estradiol, which occur in peripheral adipose tissue Classification - Simple or complex hyperplasia without atypia - Simple or complex hyperplasia with atypia
27
Cancer
Approx 5-10% of PMB is endometrial cancer Incidence increases with age Adenocarcinoma of the endometrium is the most common genital cancer in women over 45 years of age
28
Management of post-menopausal bleeding
Exclusion of cancer is the main objective; therefore, treatment is usually unnecessary once cancer) or premalignant histology) has been excluded Atrophy - Vaginal estrogen therapy Endometrial polyp - Polypectomy Endometrial hyperplasia - Cyclic progestin therapy Endometrial hyperplasia with atypia - Hysterectomy Carcinoma of endometrium - Hysterectomy with BSO and LND for staging
29
terms related to the timing of menopause
Perimenopause – time leading up to menopause -0 the time when ovarian function and hormone production are declining but have not yet stopped Menopause: a permanent cessation of the menstrual cycle Greek “meno” (month) and “pausis” (a pause) Defined as not having a period for 12 months Post menopause: time in woman’s life after last period Premature menopause: menopause occurring before age 40
30
Menopause-Related Changes
Vasomotor symptoms- hot flshes Sleep quality Mood changes Urogenital symptoms Sexual well-being Skin changes
31
Meno-myths
``` Menopause signifies old age Women go crazy at menopause A woman’s sex life is over at menopause Menopause always causes weight gain Menopause is a medical condition that always needs to be treated ```
32
conditions resulting from estrogen deficiency
``` Well Established: Vasomotor Symptoms Urogenital Disorders CHD Risk Factor (Lipids) Skin Changes ``` Association: Cardiovascular Disease Bone Loss/Osteoporosis
33
consequences of decreased progesterone
``` Irregular periods Premenstrual syndrome (PMS) ```
34
consequences of decreased androgens
``` Decrease in mood Diminished energy Impaired sexuality Muscle weakness Osteopenia ```
35
Risks and benefits of ht
It is known with good certainty that HT does not increase CHD risk in women who initiate therapy close to the onset of menopause( within-5 years of last menses) HT does not prevent and may increase the risk of CHD in women who initiate therapy years after menopause VTE is an infrequent but well established risk of HT Risk increases approximately 2-fold with HT use Greatest risk occurs in the first year of use Absolute risk remains low in HT users due to the low baseline incidence of VTE in the general, non-hospitalized population
36
Diseases Associated with Menopause
Coronary Heart Disease Osteoporosis Breast Cancer (?) Colon Cancer (?) Dementia (?)
37
New Studies: CAD
Age at initiation of HT determines cardiovascular risk is confirmed Initially thought to increase risk However, 18.3% of never-users vs 6.9% of HT users died during follow-up Starting early equals the most benefit. JAMA 2007: Women who initiated hormone therapy closer to menopause tended to have reduced CHD risk compared with the increase in CHD risk among women starting HRT more distant from menopause.
38
Hormone therapy for dementia
Critical window! Estrogen protects against dementia when taken early in peri-menopause or early in menopause. In contrast to WHI – (mean age of initiation was 63)
39
Estrogen-Progestin HT and breast cancer
A WHI analysis confirms a small risk of breast cancer mortality with estrogen-progestin HT E/P hazard risk was 1.26 in WHI Now, after follow up for 11 years, combination HT users have similar risk vs. nonusers Tumors more likely node +
40
Unopposed estrogen and breast cancer
Estrogen only HT has different risk for breast cancer than E/P HT. Estrogen only HT decreases risk in all age groups, but benefits younger women more. (Young = 60 years or less and within 10 years of menopause onset)
41
estrogen and risks of VTA, CVA
E3N student has shown no increased risk of VTE Risk of CVA similar to non-users And in fact, decreased
42
Transdermal estrogen
The authors believe evidence will eventually point to a superior safety profile for transdermal estrogen vs oral Offer estradiol gel or spray if patch causes irritation (should have same safety profile) Micronized progesterone appears safer when progesterone is required
43
Options for Mild Vasomotor Symptoms
``` For mild vasomotor symptoms Lifestyle changes (limited efficacy) Nonprescription remedies—tested only short term with little efficacy over placebo but no evidence of harm Dietary isoflavones Black cohosh Vitamin E ```
44
Options for Moderate-to-Severe Vasomotor Symptoms
``` Hormone therapy is the only FDA-approved treatment “gold standard” SSRIs and gabapentin early studies show efficacy women studied have fewer hot flashes than those in HT trials Progestogens effective however, large doses required Clonidine (oral or transdermal) ```
45
Duration of HT Use
FDA 20031 Recommends shortest duration and lowest dose consistent with treatment goals ACOG 20042 The lowest effective estrogen dose should be used for the shortest possible time to alleviate symptoms NAMS 20043 Recommends duration and dose consistent with treatment goals
46
American College of Obstetricians and Gynecologists on HT
Hormone therapy remains an effective therapy for treating women with vasomotor symptoms and vaginal atrophy. The benefits and risks should be discussed in detail with each patient before initiating therapy and when renewing her annual prescription so that she can make the best decision for her own health.”
47
Recommendations from the ACOG Task Force on HT
For women who need or prefer an alternative to HT, data support the use of bisphosphonates or SERMs In women with menopausal symptoms, HT may be appropriate as a first choice of therapy All women should be advised to have adequate intake of vitamin D and calcium intake of at least 1,000–1,500 mg/d After discontinuation of HT or bisphosphonates, the effect of HT withdrawal on bone density should be assessed
48
HCG and normal/ abnormal pregnancy
If normal – HCG should double every 48 hours If abnormal – HCG can stay the same, decrease, or increase minimally
49
Normal pregnancy - what we see
1ST Trimester bleeding(threatened abortion aka threatened miscarriage) Physical Findings – cervical os closed, cardiac activity Transvaginal US – Gestational Sac at 1,500 – 2,000 MIU
50
Risk associated with1st trimester bleeding
Miscarriage Abnormal placental implantation IUGR
51
Abnormal pregnancy(in uterus)
Missed abortion Complete abortion Incomplete abortion Molar pregnancy
52
Risk factors for spontaneous abortion
``` Maternal age Age 20 to 30 years (9 to 17 percent), age 35 years (20 percent), age 40 years (40 percent), and age 45 years (80 percent) Previous spontaneous abortion ? Increasing gravidity Prolonged time to implantation interval Prolonged time to conception Smoking >10 cigarettes per day EtOH Cocaine NSAIDs around time of conception Caffeine Low folate levels Extremes of maternal weight Fever during early pregnancy Unrecognized celiac disease ```
53
Fetal Etiologyof Sp. Ab.
Chromosomal abnormalities 50% of all spontaneous abortions Most commonly due to aneuploidies - 52% autosomal trisomy; 19% monosomal X; 22$ polyploidies - Trisomy 16 is most common, almost always lethal Congenital abnormalities Trauma - Consider chronic villus sampling and amniocentesis
54
Maternal etiology of sp. Ab.
Uterine structural issues - Ex: uterine septum, sub mucosal leiomyoma, intrauterine adhesions Acute maternal infections - Ex: Listeria monocytogenes, Toxoplasma gondii, parvovirus B19, rubella, herpes simplex, cytomegalovirus Maternal endocrinopathies - Ex: thyroid dysfunction, Cushing’s syndrome, PCOS Hypercoagulable states: - Ex: SLE, antiphospholipiod syndrome Unexplained
55
Sx for spontaneous abortion
Vaginal bleeding Pelvic pain Absence of fetal movement (rate, as usually before movement is perceived) Incidental finding on US/hand-held Doppler
56
Work up forspontaneous abortion
Hand-held Doppler Pelvic exam - Source and severity of bleeding - Size of uterus Pelvic US - Potential predictors include: abnormal gestational sac, abnormal yolk sac, slow fetal HR, sub chorionic hematoma hCG - Single value is usually not predictive, but may be useful for BL value if dx is initially uncertain Blood type antibody screen - Administer anti-D for Rh(D) negative mothers Serum progesterone >4ng/mL is associated with a nonviable pregnancy
57
Dx of spontaneous abortion
Expectant management if dx in question The criteria for spontaneous abortion on pelvic ultrasound: - A gestational sac >25mm in mean diameter that does not contain a yolk sac or embryo - An embryo with a crown rump length (CRL) >7 mm that does not have cardiac activity --- If gestational sac or embryo are too small for these dimensions, repeat in 1-2 weeks Criteria for the diagnosis of a failed pregnancy based upon lack of development over time: - After a pelvic ultrasound showed a gestational sac without a yolk sac, absence of an embryo with heartbeat in >2 weeks - After a pelvic ultrasound showed a gestational sac with a yolk sac, absence of an embryo with a heartbeat in >11 days
58
Threatened abortion
Diagnostic criteria for spontaneous abortion are not met Vaginal bleeding has occurred and the cervical OS is closed First trimester bleeding may be associated with adverse outcomes later in pregnancy - Prognosis is worse when the bleeding is heavy or extends into the second trimester Up to 50% will miscarry Tx: bed rest and expectant management
59
Inevitable abortion
Symptoms of vaginal bleeding, crampy pelvic pain, and dilated cervix - Products of conception can often be felt or visualized through the internal cervical os - No passage of fetal tissue per os Tx options: - Medical abortion - -- Usually with Misoprostol (one time dose of 800 mcg per vaginum, or 600 mcg sublingual) - Surgical abortion - -- D&C or D&E; Doxycycline 100mg Po for two doses 12 hours part on the day of the procedural to decrease risk of postabortal sepsis - Expectant management: - -- Majority of expulsions occur in the first two weeks after diagnosis
60
Incomplete abortion
Vaginal bleeding and/or pain are present, the cervix is dilated, and products of conception are found within the cervical canal on examination After 12 weeks , the membranes often rupture, and the fetus is passed, but significant amounts of placental tissue may be retained, leading to an incomplete abortion Tx options: - Medical abortion - -- Usually with Misoprostol (one time dose of 800 mcg per vaginum, or 600 mcg sublingual) - Surgical abortion - -- D&C or D&E; Doxycycline 100mg Po for two doses 12 hours part on the day of the procedural to decrease risk of postabortal sepsis - Expectant management: - -- Usually Staph aureus or mixed infections
61
Completed abortion
Products of conception are entirely out of the uterus and cervix Cervix is closed and the uterus is small and well contracted Vaginal bleeding and pain may be mild or may have resolved More common outcome than incomplete >12 weeks gestation Tx: examination of passed tissue to confirm products of conception, transvaginal US to visualize empty uterus, follow hCG levels until zero (should halve within 48-72) hours
62
Missed abortion
Patient with or without symptoms having a closed cervical OS - Women may notice that symptoms associated with early pregnancy such as nausea, breast tenderness, etc. have abated and they do not “feel pregnant” anymore Tx options: - Medical abortion - -- Usually with Misoprostol (one time dose of 800 mcg per vaginum, or 600 mcg sublingual) - Surgical abortion - -- D&C or D&E; Doxycycline 100mg Po for two doses 12 hours part on the day of the procedural to decrease risk of postabortal sepsis - Expectant management: - -- Majority of expulsions occur first two weeks after diagnosis
63
Risk factors for ectopic pregnancy
``` Previous Ectopic * PID (worst agent is chlamydia) Assisted Reproductive Technology History of peritonitis Smoking Previous Tubal Ligation ``` Note-- IUD does not increase risk
64
Treatment for Ectopic pregnancy
Medical – Methotrexate – Folic acid inhibitor Surgical – Removal of ectopic Removal of tube * future fertility is identical